The forecast for the number of multidrug-resistant tuberculosis (MDR-TB) cases started on treatment in China shows a gradually increasing trend from 2024 to 2028, with projected cases rising from 16.61 thousand in 2024 to 20.18 thousand in 2028. Assuming that actual cases in 2023 were close to the value in 2024, this represents a robust growth trajectory.
Year-on-year percentage increases indicate a consistent rise, while the compound annual growth rate (CAGR) reflects an average increase of approximately 4.9% per annum over the five-year period.
Future trends to watch for include advancements in diagnostic technologies, the potential impact of healthcare policies aimed at MDR-TB, and global partnerships to tackle infectious diseases. Monitoring these factors will be crucial in projecting long-term changes in MDR-TB treatment rates.
